The popular drugs, originally developed to treat diabetes, were also associated with an improved survival rate. Benefits were seen in patients who did and did not lose significant weight as a result of treatment. 

Published in Clinical Imaging, the responses indicate that Trump administration policies have made it more difficult to acquire funding and collaborate with other researchers. 

Two separate studies explored the value of treating heart patients with tirzepatide. 

The percentage of pregnant patients taking low-dose aspirin as recommended is slowly rising—but there is still a long way to go.

The combination of OCT and MRI can help provide an improved sense of clarity when managing MINOCA patients, according to new data presented at ACC.26 in New Orleans.

Late-breaking data out of ACC.26 suggest a more aggressive treatment approach for these patients could be beneficial. 

Heart Rhythm 2026 in Chicago will include a total of 18 late-breaking clinical trials—and that is just the beginning. The four-day event kicks off April 23.

Gregg Stone, MD, spoke to Cardiovascular Business about the lessons he and his colleagues learned from the STEMI DTU trial.